TLSA vs. DAWN, TNGX, IMTX, NRIX, OCS, NAGE, VALN, GYRE, GHRS, and VIR
Should you be buying Tiziana Life Sciences stock or one of its competitors? The main competitors of Tiziana Life Sciences include Day One Biopharmaceuticals (DAWN), Tango Therapeutics (TNGX), Immatics (IMTX), Nurix Therapeutics (NRIX), Oculis (OCS), Niagen Bioscience (NAGE), Valneva (VALN), Gyre Therapeutics (GYRE), GH Research (GHRS), and Vir Biotechnology (VIR). These companies are all part of the "pharmaceutical products" industry.
Tiziana Life Sciences vs. Its Competitors
Tiziana Life Sciences (NASDAQ:TLSA) and Day One Biopharmaceuticals (NASDAQ:DAWN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.
Tiziana Life Sciences has a beta of -0.36, indicating that its share price is 136% less volatile than the S&P 500. Comparatively, Day One Biopharmaceuticals has a beta of -1.25, indicating that its share price is 225% less volatile than the S&P 500.
Tiziana Life Sciences has a net margin of 0.00% compared to Day One Biopharmaceuticals' net margin of -50.63%. Tiziana Life Sciences' return on equity of 0.00% beat Day One Biopharmaceuticals' return on equity.
Tiziana Life Sciences has higher earnings, but lower revenue than Day One Biopharmaceuticals.
Day One Biopharmaceuticals has a consensus price target of $25.29, indicating a potential upside of 259.89%. Given Day One Biopharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Day One Biopharmaceuticals is more favorable than Tiziana Life Sciences.
88.0% of Day One Biopharmaceuticals shares are held by institutional investors. 39.8% of Tiziana Life Sciences shares are held by company insiders. Comparatively, 6.2% of Day One Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Tiziana Life Sciences had 5 more articles in the media than Day One Biopharmaceuticals. MarketBeat recorded 7 mentions for Tiziana Life Sciences and 2 mentions for Day One Biopharmaceuticals. Day One Biopharmaceuticals' average media sentiment score of 1.81 beat Tiziana Life Sciences' score of 0.41 indicating that Day One Biopharmaceuticals is being referred to more favorably in the news media.
Summary
Tiziana Life Sciences and Day One Biopharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.
Get Tiziana Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TLSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tiziana Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:TLSA) was last updated on 9/16/2025 by MarketBeat.com Staff
